Side-by-side · Research reference
MT-1vsTB-500
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED9/51 cited
BPhase 2HUMAN-REVIEWED8/46 cited
MT-1
α-MSH Analogue · FDA-Approved
SQ Implant · 60-Day Release
TB-500
Thymosin β4 fragment · Healing
SQ or IM · Multiple sites · 2–3×/week
01Mechanism of Action
Parameter
MT-1
TB-500
Primary target
Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010
G-actin (sequestering) + cell-surface integrinsGoldstein 2012
Pathway
α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis
Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012Malinda 1999
Downstream effect
Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010
Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012
Feedback intact?
Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production
Endogenous protein at baseline; supplementation amplifies
Origin
Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026
17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012
Antibody development
—
—
02Dosage Protocols
Parameter
MT-1
TB-500
Standard dose
16 mg subcutaneous implant
FDA-approved formulation (Scenesse).
2 mg per injectionGoldstein 2012
Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.
Frequency
Every 60 days
Sustained release implant — no daily administration required.
2× per week (loading); then 1× per week (maintenance)
Evidence basis
Phase 3 RCT / FDA-approved orphan drug
Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012
Indication
Erythropoietic protoporphyria (EPP)
Narrow FDA approval — not licensed for cosmetic tanning.
—
Duration
Seasonal use (spring–autumn typical)
Aligned with peak UV exposure months.
4–8 weeks loading; longer maintenance for chronic injury
Route
Subcutaneous implant — upper arm or abdomen
—
Stability
Norleucine/D-Phe substitutions enhance peptidase resistance
Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).
—
Lower / starter dose
—
1 mg per injection
Reconstitution
—
Bacteriostatic water, 1–2 mL per 5 mg vial
Timing
—
Evening or pre-rest preferred (anecdotal)
Half-life
—
~2 hours (estimated; tissue uptake longer)
04Side Effects & Safety
Parameter
MT-1
TB-500
Nausea
Common (>10%) — mild, transient
—
Implant site reaction
Erythema, bruising, tenderness at insertion site
—
Hyperpigmentation
Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010Habbema 2017
Expected melanogenic response — complicates pigmented lesion surveillance.
—
Melanocytic changes
Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017
Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.
—
Headache
Occasional (MC1R-independent melanocortin effects)
—
Photosensitivity (paradoxical)
Rare phototoxic reactions despite melanin increase
—
Contamination risk (unregulated)
Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010Habbema 2017
Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.
—
Injection site reaction
—
Mild erythema, transient pain
GI symptoms
—
Rare nausea (anecdotal)
Cancer risk
—
Theoretical via angiogenesis pathway
Lethargy / fatigue
—
Reported anecdotally during loading phase
Antibody formation
—
No data (no long-term human trials)
Pregnancy / OB
—
Avoid
Long-term safety
—
Unknown beyond Phase 2
Absolute Contraindications
MT-1
- ·Hypersensitivity to afamelanotide or excipients
- ·Hepatic impairment (no safety data)
- ·Renal impairment (no safety data)
TB-500
- ·Active malignancy (theoretical angiogenesis concern)
- ·Pregnancy / breastfeeding
Relative Contraindications
MT-1
- ·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
- ·Pregnancy/lactation (insufficient data)
- ·Photosensitive dermatoses (other than EPP)
TB-500
- ·Cancer history
- ·Concurrent VEGF inhibitor therapy
05Administration Protocol
Parameter
MT-1
TB-500
1. Implant insertion
Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.
Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.
2. Site care
Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.
SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.
3. Release kinetics
Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.
Evening or pre-sleep is most common anecdotal timing.
4. Repeat dosing
New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
5. Monitoring
Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.
27–31G, 4–8 mm insulin syringe.
06Stack Synergy
MT-1
— no documented stacks
TB-500
+ BPC-157
StrongTB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.
- TB-500
- 2 mg SQ · 2× per week
- BPC-157
- 250–500 mcg SQ · daily
- Primary benefit
- Combined angiogenesis + cell migration for tendon/ligament/muscle repair